Chemical Agent for Peripheral Nerve Lesion Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to reliably distinguish between peripheral nerve injuries that will spontaneously resolve and those requiring surgical intervention, leading to delayed surgical decisions and reduced functional outcomes.
Innovation Solution
A diagnostic imaging method involving a chemical agent that binds specifically to peripheral nerve lesions with compromised blood-nerve barriers, using monoclonal antibodies and magnetic resonance imaging to differentiate between lesions with self-regeneration potential and those requiring surgical intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional observation methods are used to monitor peripheral nerve injuries, then surgical intervention decisions are made conservatively, but the time delay reduces functional recovery outcomes
Solution Approach 1:
The patent applies preliminary action by introducing a chemical agent that binds to peripheral nerve lesions before the natural observation period expires. This agent accumulates at the injury site and enables early detection through MRI, allowing surgical intervention decisions to be made before the 18-month motor end-plate demise threshold, thereby converting a reactive observation approach into a proactive diagnostic approach that accelerates treatment without compromising accuracy
Solution Approach 2:
The patent uses a chemical agent as an intermediary substance that mediates between the peripheral nerve lesion and the MRI detection system. This agent binds specifically to compounds at the injury site where the blood-nerve barrier is compromised, translating biological injury characteristics into detectable MRI signals, thereby enabling early and accurate diagnosis without requiring prolonged observation periods
2Productivity
If early surgical intervention is performed based on accurate diagnosis, then functional recovery is improved, but reliable early diagnosis methods are currently unavailable
Solution Approach 1:
The patent applies local quality by using a chemical agent that selectively binds to compounds at the specific location of peripheral nerve lesions where the blood-nerve barrier is compromised. This localized binding creates a concentrated signal at the injury site that is distinguishable from surrounding healthy tissue, enabling precise diagnostic imaging that accurately differentiates between injuries requiring surgery and those that will resolve spontaneously
Solution Approach 2:
The chemical agent serves as an intermediary that bridges the gap between the biological injury and the MRI detection system. By binding to compounds at the lesion site and accumulating there, it converts subtle biological changes into detectable MRI signals, thereby achieving high measurement precision in diagnosing peripheral nerve injuries that would otherwise be indistinguishable from healthy tissue using conventional MRI alone
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early and accurate identification of nerve injuries needing surgical intervention, allowing timely surgery and improving functional recovery by differentiating between regenerative and non-regenerative lesions.
Implementation Method 1
using monoclonal antibodies and magnetic resonance imaging to differentiate between lesions with self-regeneration potential and those requiring surgical intervention
Data Source
AI summary
An improved method for diagnosing and characterizing peripheral nerve lesions to permit early identification and characterization of peripheral nerve injuries that will require surgical intervention.